Lincoln Pharmaceuticals (531633) Q4 99/00 earnings summary

Executive summary

• FY2000 sales rose to Rs. 3,138.88 lakh from Rs. 2,533.95 lakh; net profit increased to Rs. 150.51 lakh from Rs. 138.24 lakh.

• Directors recommended retaining resources and paying no dividend.

Financial highlights

• Revenue from sales was Rs. 3,138.88 lakh vs. Rs. 2,533.95 lakh; total income was Rs. 3,184.76 lakh vs. Rs. 2,707.64 lakh.

• Profit before tax was Rs. 176.51 lakh vs. Rs. 167.82 lakh; profit after tax was Rs. 150.51 lakh vs. Rs. 138.24 lakh.

• Materials consumption was Rs. 1,759.42 lakh vs. Rs. 1,447.55 lakh; sales and administrative expenses were Rs. 309.61 lakh vs. Rs. 288.58 lakh.

Segment performance

• Export sales were Rs. 524.61 lakh vs. Rs. 598.10 lakh; domestic sales were Rs. 2,614.27 lakh vs. Rs. 1,935.84 lakh.

• Primaquine tablet production was 88.45 million units vs. 60 million; D-cold Syrup production was 2.40 million bottles vs. 2.24 million.

• Turnover included Rs. 21.64 lakh from D-cold Syrup, Rs. 155.96 lakh from Primaquine and Rs. 2,766.55 lakh from other products.